Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology

Abstract EN

Background.

Polycystic ovary syndrome (PCOS) is the most common female endocrine disease.

Cangfu Daotan Decoction (CDD) can effectively relieve the clinical symptoms of PCOS patients.

Methods.

To explore the active ingredients and related pathways of CDD for treating PCOS, a network pharmacology-based analysis was carried out.

The active ingredients of CDD and their potential targets were obtained from the TCM system pharmacology analysis platform.

The obtained PCOS-related genes from OMIM and GeneCards were imported to establish protein-protein interaction networks in STRING.

Finally, GO analysis and significant pathway analysis were conducted with the RStudio (Bioconductor) database.

Results.

A total of 111 active compounds were obtained from 1433 ingredients present in the CDD, related to 118 protein targets.

In addition, 736 genes were found to be closely related to PCOS, of which 44 overlapped with CDD and were thus considered therapeutically relevant.

Pathway enrichment analysis identified the AGE-RAGE signalling pathway in diabetic complications, endocrine resistance, the IL-17 signalling pathway, the prolactin signalling pathway, and the HIF-1 signalling pathway.

Moreover, PI3K-Akt, insulin resistance, Toll-like receptor, MAPK, and AGE-RAGE were related to PCOS and treatment.

Conclusions.

CDD can effectively improve the symptoms of PCOS, and our network pharmacological analysis lays the foundation for future clinical research.